AROLDI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 4.128
AS - Asia 3.211
EU - Europa 2.346
SA - Sud America 467
Continente sconosciuto - Info sul continente non disponibili 136
AF - Africa 84
OC - Oceania 10
Totale 10.382
Nazione #
US - Stati Uniti d'America 3.909
IT - Italia 1.069
VN - Vietnam 913
SG - Singapore 851
CN - Cina 594
BR - Brasile 348
HK - Hong Kong 310
RU - Federazione Russa 268
DE - Germania 230
SE - Svezia 141
CA - Canada 137
IE - Irlanda 134
BD - Bangladesh 115
GB - Regno Unito 96
FR - Francia 92
IN - India 87
KR - Corea 58
ES - Italia 56
FI - Finlandia 50
AR - Argentina 45
NL - Olanda 44
PL - Polonia 44
ID - Indonesia 39
MX - Messico 38
ZA - Sudafrica 35
IQ - Iraq 34
TR - Turchia 30
JP - Giappone 29
CH - Svizzera 26
PH - Filippine 25
PK - Pakistan 21
AT - Austria 20
SA - Arabia Saudita 19
UA - Ucraina 19
CO - Colombia 17
VE - Venezuela 17
UZ - Uzbekistan 15
EC - Ecuador 13
EG - Egitto 11
LT - Lituania 10
CR - Costa Rica 9
CZ - Repubblica Ceca 9
AU - Australia 8
CL - Cile 8
KE - Kenya 8
PT - Portogallo 8
AE - Emirati Arabi Uniti 7
ET - Etiopia 7
HN - Honduras 7
PY - Paraguay 7
IR - Iran 6
MA - Marocco 6
DO - Repubblica Dominicana 5
IL - Israele 5
NO - Norvegia 5
NP - Nepal 5
RO - Romania 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
JM - Giamaica 4
KG - Kirghizistan 4
KZ - Kazakistan 4
MY - Malesia 4
PE - Perù 4
TH - Thailandia 4
UY - Uruguay 4
BG - Bulgaria 3
BO - Bolivia 3
CY - Cipro 3
GR - Grecia 3
JO - Giordania 3
MU - Mauritius 3
NI - Nicaragua 3
RS - Serbia 3
AM - Armenia 2
AO - Angola 2
BH - Bahrain 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DZ - Algeria 2
GT - Guatemala 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MM - Myanmar 2
MT - Malta 2
NG - Nigeria 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SV - El Salvador 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AL - Albania 1
BB - Barbados 1
BE - Belgio 1
FJ - Figi 1
GD - Grenada 1
Totale 10.232
Città #
Ann Arbor 545
Singapore 475
Ashburn 440
San Jose 389
Milan 372
Ho Chi Minh City 279
Hong Kong 279
Hanoi 255
Dallas 214
Los Angeles 172
New York 148
Dublin 134
Frankfurt am Main 131
Hefei 119
Chandler 86
Council Bluffs 85
Beijing 84
Santa Clara 80
Toronto 80
Chicago 71
Fairfield 71
Wilmington 69
Woodbridge 65
Columbus 57
Rome 56
Seoul 56
Houston 50
The Dalles 40
Lauterbourg 39
Seattle 39
São Paulo 38
Buffalo 35
Boardman 34
Haiphong 34
Shanghai 32
Jakarta 30
Munich 30
Warsaw 29
Phoenix 28
Johannesburg 27
Montreal 27
Kent 26
Orem 26
Tokyo 25
Princeton 24
Turin 24
Atlanta 23
Biên Hòa 22
Poplar 21
Cambridge 20
Helsinki 20
Monza 20
Zurich 20
Lissone 19
Moscow 19
Da Nang 18
London 18
Chennai 17
Guangzhou 17
Nuremberg 17
Thái Nguyên 17
Turku 17
Brooklyn 16
Desio 16
Ha Long 16
Hải Dương 16
Sesto San Giovanni 16
Baghdad 15
Ninh Bình 15
Rio de Janeiro 14
Romola 14
Stockholm 14
Amsterdam 13
Denver 13
Lawrence 13
Seveso 13
Figino 12
Quận Bình Thạnh 12
Salt Lake City 12
Tashkent 12
Altamura 11
Bologna 11
Bắc Ninh 11
Jacksonville 11
Lappeenranta 11
Can Tho 10
Mexico City 10
Newburgh 10
Riyadh 10
Bogotá 9
Curitiba 9
Genoa 9
Miami 9
Naples 9
Querétaro 9
San Diego 9
Washington 9
Bắc Giang 8
Charlotte 8
Como 8
Totale 6.197
Nome #
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 474
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 435
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 403
Idiopathic erythrocytosis: a germline disease? 397
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 396
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 382
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 379
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 345
Chronic myeloid leukemia: Second-line drugs of choice 337
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 336
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 334
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 322
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy 318
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 302
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 292
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 290
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 286
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea 277
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 269
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 265
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 255
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 254
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 250
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 237
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 235
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 235
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 232
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 231
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 228
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 225
Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options 210
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 192
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells 156
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 152
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) 152
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors 125
Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models 103
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution 71
Totale 10.382
Categoria #
all - tutte 30.580
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.580


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022207 0 0 48 38 14 23 4 8 7 10 17 38
2022/2023421 37 117 37 27 24 62 29 8 35 12 26 7
2023/2024650 14 20 30 27 61 175 96 25 67 42 26 67
2024/20251.883 56 141 88 76 119 88 113 69 170 323 213 427
2025/20265.590 887 456 456 708 495 222 769 223 340 462 224 348
2026/2027700 314 299 87 0 0 0 0 0 0 0 0 0
Totale 10.382